Navigation Links
New Collaboration Aims To Expand Seed-Based Technologies, Benefit Farmers

ST. LOUIS and DURHAM, N.C., Jan. 27 /PRNewswire-FirstCall/ -- As farmers look to get more out of each acre of farmland, St. Louis-based Monsanto (NYSE: MON) is exploring unique ways to discover and deliver more desirable traits through the seed. Monsanto's new collaboration with GrassRoots Biotechnology Inc. is expected to do just that by expanding the benefits of Monsanto's research and product portfolio for its farmer customer.

Today, Monsanto announced that it has established a three-year collaboration with GrassRoots Biotechnology Inc., based in Research Triangle Park, North Carolina, to source novel genetic elements, including promoters and genes, which can enable crops to express traits that enhance and protect yield.

Promoters are segments of DNA that determine when and where a trait is expressed within a plant. Monsanto will use the promoters sourced from GrassRoots in a broad range of crops, including corn, soy, cotton and canola, to optimize an array of biotechnology traits.

GrassRoots is a start-up company co-founded by Duke University professor, Philip Benfey, a leader in plant biology research. GrassRoots uses a variety of methods, including computational approaches, to identify promoter candidates. Once specific promoter sequences are identified, the information can be further used to design novel promoters for the expression of desirable traits in plants.

"The availability of high-quality promoters with specific expression patterns for use in commercial products is limited, so there is value in developing novel promoters to drive new traits," said Steve Padgette, vice president of biotechnology for Monsanto.

"A robust promoter toolbox can further leverage Monsanto's extensive gene library and lead to the development of more biotechnology-based crop products with a greater number of characteristics such as higher yield, and tolerance to insects, weeds and other stresses," Padgette said.

Such tools will be critical in helping Monsanto meet its sustainability goal of doubling yields in core crops by 2030, he said.

"We will need to use the best technologies available to maximize the potential of these crops," Padgette said.

Another goal of the collaboration is to identify genes that help plants fight environmental stresses such as nitrogen deficiency. The collaboration is expected to build upon Monsanto's research philosophy of developing valuable families of technologies for the challenges farmers routinely face on farm.

"We are excited to form an alliance with Monsanto," said Philip Benfey, president and chief executive of GrassRoots. "Our technologies and expertise combined with Monsanto's commercialization pipeline will provide a means of rapidly moving new genes and promoters into the field."

About Monsanto Company

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. Monsanto remains focused on enabling both small-holder and large- scale farmers to produce more from their land while conserving more of our world's natural resources such as water and energy. To learn more about our business and our commitments, please visit: .

About GrassRoots Biotechnology

GrassRoots Biotechnology, Inc. is a start-up company based in Research Triangle Park, NC. The company was founded to advance and commercialize technologies developed by co-founder Dr. Philip Benfey in his laboratory at Duke University. GrassRoots' core technology, the RootArray system, makes it possible to monitor gene expression within developing plant roots, thus providing new insight into the mechanism of genetic control of plant development. The RootArray facilitates the discovery of genes and gene promoters that could produce higher-yielding crops better able to withstand environmental stresses, like drought and nitrogen deficiency.

GrassRoots also is developing an energy program to create enhanced biofuel crops. Independently, GrassRoots is developing a bioenergy research program. The company is creating enhanced biofuel feedstocks with increased biomass, more accessible cellulose to facilitate processing, and roots that sequester greater amounts of carbon.

Forward-Looking Statements:

Certain statements contained in this press release are forward-looking statements, such as statements concerning the company's future product performance, regulatory approvals, business and financial plans and other non- historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: the success of the companies' research and development activities; the costs of and the companies' abilities to access and enforce intellectual property needed for the collaboration; the costs and requirements of regulatory compliance and the speed with which approvals are received; public acceptance of biotechnology products; and other risks and factors detailed in the company's most recent periodic report to the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this presentation. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.

SOURCE Monsanto Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix Signs Collaboration With Battelle
2. Cosun and Avantium Announce Collaboration
3. Canadas Genome Centres Promote Collaboration at International Conference
4. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
5. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
6. Pressure BioSciences, Inc. and the J. Craig Venter Institute Announce Collaboration Agreement & Purchase of a PCT System
7. OmegaGenesis Announces Angiogenesis Application Collaboration
8. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
9. Sigma-Aldrich Enters Into Research Collaboration Program With D-Finitive Cell Technologies, Inc., to Develop Research Tools for Regenerative Medicine
10. ChemDiv and Avineuro Extend Collaboration on Alzheimers Disease and Schizophrenia
11. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Post Your Comments:
(Date:12/1/2015)...  CardioCell LLC, a Stemedica Cell Technologies Inc. ... indications, intends to proceed with finalizing a Phase ... a Heart Failure Advisory Board comprising cardiology key ... members . In a recent meeting members of ... efficacy data from CardioCell,s on-going chronic heart failure ...
(Date:12/1/2015)... Frederick, MD (PRWEB) , ... December 01, 2015 ... ... management solutions provider, announces that its best selling system laboratory animal colony management ... ezColony® Cloud today, without investing in on-site IT resources., , ...
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  Symic, ... and affect the extracellular matrix (ECM), today announced that ... financing to advance the company,s pipeline, including its lead ... Lilly Ventures and includes the participation by all existing ... new funding brings the total capital raised by Symic ...
(Date:12/1/2015)... , December 1, 2015 Dr. Harry Lander , President ... serving as Chief Science Officer and recruits five ... Harry Lander , President of Regen, expands his role to ... recruits five distinguished scientists to join advisory team ... expands his role to include serving as ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
Breaking Biology News(10 mins):